About the Company
durect is a specialty pharmaceuticals company with expertise in drug discovery, drug delivery and drug development, applying those skills primarily to therapeutics in the fields of pain management, acute organ injury and metabolic diseases. durect’s proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as improved abuse deterrence, convenience, adherence, efficacy and safety for small molecule and biologic drugs. late stage development programs of this nature include remoxy® and posidur™. durect’s epigenomic regulator program includes the lead molecule dur-928 in phase 1 clinical testing. dur-928 is an endogenous small molecule that is an epigenomic modulator of cellular activities involved in lipid homeostasis, metabolic disease, inflammation and cell survival. for more information, please visit www.durect.com. we also manufacture and sell two commercial product lines: • alzet® osmotic pumps use
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $DRRX News
Durect Corp DRRX
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
DURECT and Charles River enter agreement for alzet in U.S., Canada
DURECT Corporation (NASDAQ:DRRX) entered into a co-marketing and collaboration agreement with Charles River Laboratories for the alzet Osmotic Pumps Portfolio and Associated Product Line in the U ...
DURECT Inks Co-marketing And Collaboration Deal With Charles River For ALZET Product Line
(RTTNews) - Biopharmaceutical company DURECT Corp. (DRRX) announced Monday that it has entered into a co-marketing and collaboration agreement with Charles River Laboratories International, Inc. (CRL) ...
DRRX Apr 2024 0.500 put
DURECT Corporation (Nasdaq: DRRX), today announced that it has entered into a co-marketing and collaboration agreement with Charles River Laboratories for the ALZET® Osmotic Pumps Portfolio and ...
DURECT Corporation to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
A link to the webcast will also be available by accessing DURECT's homepage at www.durect.com and clicking on the "Events" page under the "Investors" section. Management will be available for ...
DURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZET® Product Line in U.S. and Canada
March 4, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), today announced that it has entered into a co-marketing and collaboration agreement with Charles River Laboratories for the ALZET ...
DURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZET® Product Line in U.S. and Canada
Partnership agreement will be the first-ever co-marketing and sales collaboration for the ALZET Osmotic Pumps Portfolio and Associated Product Line in the U.S. and Canada Both companies will jointly ...
Loading the latest forecasts...